Printer Friendly

Research and Markets: Central Nervous System Disorders Therapeutics Market to 2017 - Anticipated Launch of Novel Molecules Will Drive Growth.

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/3bbd9c/central_nervous_sy) has announced the addition of the "Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010" report to their offering.

GBI Research, the leading business intelligence provider, has released its latest research Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010, which provides insights into CNS disorder therapeutics market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

The report provides an in-depth analysis of the major CNS disorder including Alzheimer's disease, multiple sclerosis, Parkinson's disease, diabetic neuropathy, major depressive disorder (MDD), bipolar disorder, schizophrenia insomnia, epilepsy, attention deficit hyperactivity disorder (ADHD) and migraine. The report also provides the share of generics in global CNS disorder therapeutics market as well as in each indication market.

The report examines the global CNS disorder treatment usage patterns. In addition, the geographical distribution of CNS disorder and market across the US, the top five countries of Europe and in Japan. The report also includes insights into the CNS disorder R&D product pipeline and explores the competitive landscape including major players in CNS disease market. Finally, the report also includes analysis on Mergers and Acquisitions (M&As) and licensing agreements that took place in CNS disorder therapeutics market.

Read more inside 'Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010'

Companies Mentioned:

* Eli Lilly

* Pfizer

* AstraZeneca

* Johnson & Johnson (J&J)

* Teva

For more information visit http://www.researchandmarkets.com/research/3bbd9c/central_nervous_sy
COPYRIGHT 2011 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 3, 2011
Words:370
Previous Article:Jomar Association Services, Inc. Adds to Company Portfolio.
Next Article:Downtown Atlanta Enters Better Buildings Challenge.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters